VP Svp IR Corp Comm positions focus on delivering results in their domain. This page aggregates open VP Svp IR Corp Comm roles and what employers typically expect.
**Job Title:** Vice President/Senior Vice President, Investor Relations and Corporate Communications **Location:** San Diego, California **Job Type:** Full-Time **Who We Are** Avenzo Therapeutics, Inc. (“**Avenzo**” or “**Company**”) is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The Company was co-founded in 2022 by Drs. Athena Countouriotis and Mohammad Hirmand (former CEO and CMO of Turning Point Therapeutics, Inc., respectively). Our team is passionate about and committed to advancing a pipeline of potentially differentiated targeted oncology programs that make a difference in the lives of people with cancer. The Company is headquartered in San Diego, California. **Position Summary** The Vice President/Senior Vice President, Investor Relations and Corporate Communications will develop and execute the Company’s investor relations and corporate communications strategies as we prepare for transition to operating as a public company. The candidate will serve as a key advisor to the CEO, CFO, and the Board on investor sentiment, shareholder communications, and market positioning, and act as the primary point of contact for the investment community. In addition, the candidate will shape and communicate the corporate narrative to support the Company’s long-term growth and strategic objectives, ensuring consistent, compelling, and credible communication across all stakeholders. This position will report to the CEO or to the CFO, depending on the Company’s organizational structure. **Essential Job Functions and Responsibilities** - Develop and execute a comprehensive investor relations strategy aligned with corporate objectives and long-term value creation - Build and cultivate strong relationships with the investment community to ensure accurate understanding of the Company’s strategy, clinical pipeline, and regulatory milestones - Organize and manage investor conferences, non-deal roadshows, analyst meetings, investor events, and other external engagement activities - Develop and execute an integrated corporate communications strategy that enhances the company’s visibility, credibility, and reputation - Prepare and oversee quarterly earnings materials, investor presentations, scripts, press releases, Q&A documents, and other external communications - Lead communication planning around key corporate milestones, including clinical data readouts, regulatory submissions, approvals, partnerships, and financing events - Monitor market trends, peer performance, analyst commentary, and investor sentiment within the biotechnology sector - Provide strategic insights and feedback to executive leadership and the Board regarding market positioning and investor perceptions - Prepare senior leadership for earnings calls, investor conferences, non-deal roadshows, and other investor interactions - Collaborate cross-functionally with Finance and Legal to support the timely and compliant execution of external financial disclosures and investor communications, ensuring adherence to SEC regulations, disclosure requirements, and public company best practices - Manage external agencies and consultants, as applicable, including budgeting and performance oversight **Preferred Qualifications** - Bachelor’s degree required; advanced degree in Finance, Business, Communications, or a related area degree preferred (e.g., M.S., Ph.D., M.B.A.) with 20+ years of relevant experience in life sciences industry or an equivalent combination of academic and industry experience - Significant experience leading public company investor relations and corporate communications, including public company transition - Proven experience interacting with or within biotechnology-focused institutional investors and/or sell-side research analysts strongly preferred - Demonstrated ability to communicate complex scientific and financial information clearly and effectively to investors, analysts, and executive stakehol…